• Barinthus flagged a Nasdaq continued-listing issue tied to its planned Scheme of Arrangement and related corporate actions.
• England and Wales High Court sanctioned the Scheme of Arrangement and a share premium account capital reduction on Sept. 1, 2026.
• Scheme now expected to become effective Sept. 9, 2026.
• Nasdaq trading in the company’s American depositary shares expected to halt before the open on Sept. 9, 2026.
• Delisting and deregistration plans for the ADSs remain unchanged.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Barinthus Biotherapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-104368), on September 01, 2026, and is solely responsible for the information contained therein.